Capricor Therapeutics Sued for Misleading Investors Over Deramiocel Therapy Projections

Capricor Therapeutics Faces Class Action Lawsuit Amid Allegations of Misleading Investors

Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit initiated by Levi & Korsinsky, LLP, aimed at recovering losses for investors allegedly misled by the company about its lead cell therapy candidate, deramiocel. The lawsuit, which covers the period from October 9, 2024, to July 10, 2025, claims that Capricor provided overly optimistic projections regarding its chances of securing a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). These assertions reportedly obscured crucial adverse information, particularly the results from its Phase 2 HOPE-2 trial, which raised significant concerns about the safety and efficacy of deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

On July 11, 2025, the situation escalates when Capricor announces it received a Complete Response Letter (CRL) from the FDA. This letter indicates that the company failed to provide sufficient evidence demonstrating the effectiveness of deramiocel, necessitating additional clinical data to support their application. The announcement leads to a sharp decline in Capricor's stock price, plummeting from $11.40 to $7.64 in a single day. This dramatic drop underscores the potential repercussions of the alleged misrepresentations made by the company, as investors respond to the sudden shift in outlook regarding the viability of its lead therapy.

The implications of this lawsuit extend beyond just financial losses for shareholders; they highlight the broader challenges faced by biotech firms in navigating the complexities of regulatory approval processes. As Capricor grapples with the fallout from the allegations, the case serves as a cautionary tale about the importance of transparency and the ethical responsibilities companies hold to their investors, especially in the volatile field of biotechnology. Investors affected by the alleged securities fraud have until September 15, 2025, to seek appointment as lead plaintiffs in the class action, which promises no upfront costs for those who choose to participate.

In related developments, Levi & Korsinsky, known for its expertise in securities litigation, emphasizes its commitment to advocating for investors and securing justice in cases of corporate misconduct. The firm has a proven track record of achieving substantial settlements, making it a prominent player in the realm of securities law. As the case unfolds, it raises questions about corporate governance and the accountability of biotech firms in providing accurate information to their stakeholders.